Amarin Plans Additional Miraxion Phase III Trial To Support Huntington’s NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amarin's beleaguered neuroprotective agent Miraxion (ethyl eicosapentaenoate) gained new life Nov. 15 when FDA said an additional Phase III trial might help its case for approval as a Huntington's disease therapy, the firm announced Nov. 19